Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

LAPTM4B: A novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling

Oncogene volume 29, pages 5785–5795 (2010)Cite this article

Subjects

Abstract

LAPTM4B (lysosomal protein transmembrane 4 beta) is a newly identified cancer-associated gene. Both of its mRNA and the encoded LAPTM4B-35 protein are significantly upregulated with more than 70% frequency in a wide variety of cancers. The LAPTM4B-35 level in cancer is evidenced to be an independent prognostic factor and its upregulation promotes cell proliferation, migration and invasion, as well as tumorigenesis in nude mice. In contrary, knockdown of LAPTM4B-35 expression by RNA interference (RNAi) reverses all of the above malignant phenotypes. We herein reveal a new role of LAPTM4B-35 in promoting multidrug resistance of cancer cells. Upregulation of LAPTM4B-35 motivates multidrug resistance by enhancement of efflux from cancer cells of a variety of chemodrugs with variant structures and properties, including doxorubicin, paclitaxel and cisplatin through colocalization and interaction of LAPTM4B-35 with multidrug resistance (MDR) 1 (P-glycoprotein, P-gp), and also by activation of PI3K/AKT signaling pathway through interaction of PPRP motif contained in the N-terminus of LAPTM4B-35 with the p85α regulatory subunit of PI3K. The specific inhibitors of PI3K and knockdown of LAPTM4B-35 expression by RNAi eliminate the multidrug resistance effect motivated by upregulation of LAPTM4B-35. In conclusion, LAPTM4B-35 motivates multidrug resistance of cancer cells by promoting drug efflux through colocalization and interaction with P-gp, and anti-apoptosis by activating PI3K/AKT signaling. These findings provide a promising novel strategy for sensitizing chemical therapy of cancers and increasing the chemotherapeutic efficacy through knockdown LAPTM4B-35 expression by RNAi.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Abdul-Ghani R, Serra V, Györffy B, Jürchott K, Solf A, Dietel M et al. (2006). The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1. Oncogene 25: 1743–1752.

    Article  CAS  Google Scholar 

  • Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM . (2003). P-glycoprotein: from genomics to mechanism. Oncogene 22: 7468–7485.

    Article  CAS  Google Scholar 

  • Barancík M, Bohácov V, Sedlák J, Sulov Z, Breier A . (2006). LY294,002, a specific inhibitor of PI3K/Akt kinase pathway, antagonizes P-glycoprotein-mediated multidrug resistance. Eur J Pharm Sci 29: 426–434.

    Article  Google Scholar 

  • Cabrita MA, Hobman TC, Hogue DL, King KM, Cass CE . (1999). Mouse transporter protein, a membrane protein that regulates cellular multidrug resistance, is localized to lysosomes. Cancer Res 59: 4890–4897.

    CAS  PubMed  Google Scholar 

  • Choi BH, Kim CG, Lim Y, Shin SY, Lee YH . (2007). Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NFkappaB pathway. Cancer Lett 259: 111–118.

    Article  Google Scholar 

  • Duvvuri M, Konkar S, Funk RS, Krise JM, Krise JP . (2005). A chemical strategy to manipulate the intracellular localization of drugs in resistant cancer cells. Biochemistry 44: 15743–15749.

    Article  CAS  Google Scholar 

  • Fu D, Roufogalis BD . (2007). Actin disruption inhibits endosomal traffic of P-glycoprotein-EGFP and resistance to daunorubicin accumulation. Am J Physiol. Cell Physiol 292: C1543–C1552.

    Article  CAS  Google Scholar 

  • García MG, Alaniz LD, Cordo Russo RI, Alvarez E, Hajos SE . (2008). PI3K/Akt inhibition modulates multidrug resistance and activates NF-kappaB in murine lymphoma cell lines. Leuk Res 33: 288–296.

    Article  Google Scholar 

  • Gottesman MM . (2002). Mechanisms of cancer drug resistance. Annual Rev Med 53: 615–627.

    Article  CAS  Google Scholar 

  • He J, Shao GZ, Zhou RL . (2003). Effects of the novel gene, LAPTM4B, high expression in hepatocellular carcinoma on cell proliferation and tumorigenesis of NIH3T3 cells. J Peking University (Health Sciences) 35: 348–352.

    CAS  Google Scholar 

  • Hogue DL, Ellison MJ, Young JD, Cass CE . (1996). Identification of a novel membrane transporter associated with intracellular membranes by phenotypic complementation in the yeast Saccharomyces cerevisiae. J Biol Chem 271: 9801–9808.

    Article  CAS  Google Scholar 

  • Hogue DL, Kerby L, Ling V . (1999). A mammalian lysosomal membrane protein confers multidrug resistance upon expression in Saccharomyces cerevisiae. J Biolog Chem 274: 12877–12882.

    Article  CAS  Google Scholar 

  • Kasper G, Vogel A, Klaman I, Gro J, Petersen I, Weber B et al. (2005). The human LAPTM4b transcript is up regulated in various types of solid tumours and seems to play a dual functional role during tumour progression. Cancer Lett 224: 93–103.

    Article  CAS  Google Scholar 

  • Kim H, Barroso M, Samanta R, Greenberger L, Sztul E . (1997). Experimentally induced changes in the endocytic traffic of P-glycoprotein alter drug resistance of cancer cells. Am J Physiol. Cell Physiol 273: C687–C702.

    Article  CAS  Google Scholar 

  • Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L et al. (2003). HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22: 3205–3212.

    Article  CAS  Google Scholar 

  • Larsen AK, Escargueil AE, Skladanowski A . (2000). Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther 85: 217–229.

    Article  CAS  Google Scholar 

  • Lee Jr JT, Steelman LS, McCubrey JA . (2004). Phosphatidylinositol 3′-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res 64: 8397–8404.

    Article  CAS  Google Scholar 

  • Liu XR, Zhou RL, Zhang QY, Zhang Y, Jin YY, Lin M et al. (2004). Structure analysis and expressions of a novel tetratransmembrane protein, lysosome--associated protein transmembrane 4 B. World J Gastroenterol 10: 1555–1559.

    Article  CAS  Google Scholar 

  • Liu X, Xiong F, Wei X, Yang H, Zhou R . (2009). LAPTM4B-35, a novel tetratransmembrane protein and its PPRP motif play critical roles in proliferation and metastatic potential of hepatocellular carcinoma cells. Cancer Sci 100: 2335–2340.

    Article  CAS  Google Scholar 

  • Morris DG, Musat M, Czirják S, Hanzély Z, Lillington DM, Korbonits M et al. (2005). Differential gene expression in pituitary adenomas by oligonucleotide array analysis. Eur J Endocrinol 153: 143–151.

    Article  CAS  Google Scholar 

  • Peng C, Zhou RL, Shao GZ, Rui JA, Wang SB, Lin M et al. (2005). Expression of lysosome-associated protein transmembrane 4B-35 in cancer and its correlation with the differentiation status of hepatocellular carcinoma. World J Gastroenterol 11: 2704–2708.

    Article  CAS  Google Scholar 

  • Shao GZ, Zhou RL, Zhang QY, Zhang Y, Liu JJ, Rui JA et al. (2003). Molecular cloning and characterization of LAPTM4B, a novel gene upregulatively expressed in hepatocellular carcinoma. Oncogene 22: 5060–5069.

    Article  CAS  Google Scholar 

  • Tazzari PL, Cappellini A, Ricci F, Evangelisti C, Papa V, Grafone T et al. (2007). MRP1 & PI3K/Akt multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia 21: 427–438.

    Article  CAS  Google Scholar 

  • Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H et al. (2003). Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 94: 15–21.

    Article  CAS  Google Scholar 

  • Yang TT, Sinai P, Kain SR . (1996). An acid phosphatase assay for quantifying the growth of adherent and nonadherent cells. Anal Biochem 241: 103–108.

    Article  CAS  Google Scholar 

  • Yang Y, Yang H, McNutt MA, Xiong F, Nie X, Li L et al. (2008). LAPTM4B over expression is an independent prognostic marker in ovarian carcinoma. Oncol Rep 20: 1077–1083.

    PubMed  Google Scholar 

  • Yang H, Xiong FX, Lin M, Yang Y, Nie X, Zhou RL . (2009). LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol 136: 275–281.

    Article  Google Scholar 

  • Yang H, Xiong F, Wei X, Yang Y, McNutt MA, Zhou R . (2010). LAPTM4B-35 promotes growth and metastasis of hepatocelluar carcinoma. Cancer Lett 294: 236–244.

    Article  CAS  Google Scholar 

  • Zhang XY, Zhang HY, Zhang PN, Lu X, Sun H . (2008). Elevated phosphatidylinositol 3-kinase activation and its clinicopathological significance in cervical cancer. Eur J Obstetr, Gynecol, Reprod Biol 139: 237–244.

    Article  CAS  Google Scholar 

  • Zhou L, Hea XD, Chen J, Cui QC, Qu Q, Rui JA et al. (2006). Overexpression of LAPTM4B-35 closely correlated with clinicopathological features and post-resectional survival of gallbladder carcinoma. Eur J Cancer 43: 809–815.

    Article  Google Scholar 

  • Zhou L, He XD, Cui QC, Zhou WX, Qu Q, Zhou RL et al. (2008). Expression of LAPTM4B-35: a novel marker of progression, invasiveness and poor prognosis of extrahepatic cholangiocarcinoma. Cancer Lett 264: 209–217.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from 211 and 985 Foundation of Peking University, National High-tech R&D Program (863 Program) (2006AA02A305), 248 major R&D program of Beijing (H020220020310) and NNSFC (90408018).

Author information

Author notes

  1. L Li, X H Wei and Y P Pan: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Cell Biology, School of Basic Medical Sciences, Peking University, Beijing, China

    L Li, X H Wei, Y P Pan, H C Li, H Yang, Q H He, Y Pang, Y Shan, F X Xiong, G Z Shao & R L Zhou

Authors
  1. L Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. X H Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y P Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H C Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Q H He
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Y Pang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Y Shan
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. F X Xiong
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. G Z Shao
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. R L Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R L Zhou.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Oncogene website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, L., Wei, X., Pan, Y. et al. LAPTM4B: A novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling. Oncogene 29, 5785–5795 (2010). https://doi.org/10.1038/onc.2010.303

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2010.303

Keywords

This article is cited by

Search

Advanced search

Quick links